Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01276210 · ClinicalTrials.gov registry record · Phase 1
Sorafenib Tosylate and Stereotactic Radiosurgery in Treating Patients With Brain Metastases
A Phase 1 study, sponsored by Vanderbilt-Ingram Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 23
- Enrollment target
NCT01276210 is a Phase 1 study that has completed, run by Vanderbilt-Ingram Cancer Center. The registered enrollment target is 23 participants.
The verdict
NCT01276210, a Phase 1 study, has completed, sponsored by Vanderbilt-Ingram Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 23 participants
- Enrollment target
Study Summary
RATIONALE: Sorafenib tosylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth or by blocking blood flow to the tumor. Stereotactic radiosurgery (SRS) may be able to send x-rays directly to the tumor and cause less damage to normal tissue. Giving sorafenib tosylate together with SRS may kill more tumor cells. PURPOSE: This phase I trial is studying the side effects and the best dose of sorafenib tosylate when given together with SRS in treating patients with brain metastases
Interventions
- OTHER laboratory biomarker analysis
- RADIATION stereotactic radiosurgery
- DRUG sorafenib tosylate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2011-02 |
| Est. Completion | 2017-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01276210
The ClinicalTrials.gov registry entry for NCT01276210 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 23 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vanderbilt-Ingram Cancer Center, which has 189 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which laboratory biomarker analysis is the first listed.
NCT01276210 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01276210 about?
NCT01276210 is a clinical study titled "Sorafenib Tosylate and Stereotactic Radiosurgery in Treating Patients With Brain Metastases". RATIONALE: Sorafenib tosylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth or by blocking blood flow to the tumor. Stereotactic radiosurgery (SRS) may be able to send x-rays directly to the tumor and cause less damage to normal tissue. Giving sorafenib to...
What is the current status of trial NCT01276210?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 23 participants. The study started on 2011-02. Estimated completion is 2017-06.
What interventions are being tested in trial NCT01276210?
The interventions under investigation include: laboratory biomarker analysis (OTHER), stereotactic radiosurgery (RADIATION), sorafenib tosylate (DRUG).
Who is sponsoring clinical trial NCT01276210?
This trial is sponsored by Vanderbilt-Ingram Cancer Center, which has 189 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.